Stanley Caroff, MD

Early Response With Valbenazine and Long-Term Symptom Reduction in Patients With Tardive Dyskinesia: Post Hoc Analysis of the KINECT 3 Study

Background: Valbenazine is approved for the treatment of tardive dyskinesia (TD), a persistent and disabling movement disorder associated with prolonged antipsychotic exposure. Data from ...

Khodayar Farahmand , PharmD;

Jean-Pierre Lindenmayer , MD;

Stephen Marder , MD;

Stewart Factor , DO;

Leslie Lundt , MD;

Stanley Caroff , MD;

11/22/2019

An Experimental Study to Assess the Professional and Social Consequences of Mild-to-Moderate Tardive Dyskinesia

BACKGROUND: Tardive dyskinesia (TD), a movement disorder, may arise in patients taking antipsychotics. Social and professional stigma associated with mild-to-moderate TD movements has not...

Stanley Caroff , MD;

Benjamin Carroll , PharmD;

Debbie Goldschmidt , PhD;

Fan Mu , PhD;

Michael J. Crescenz ;

Rajeev Ayyagari , PhD;

11/22/2019

Background: The impact of possible tardive dyskinesia (TD) was assessed in RE KINECT, a real-world study of antipsychotic-treated outpatients. Based on clinician assessments, patients wer...

William Lenderking , PhD;

Michael Serbin , PharmD;

Chuck Younan , PharmD;

Ericha Franey , PhD;

Andrew J. Cutler , MD;

Stanley Caroff , MD;

11/22/2019

Tardive Dyskinesia Symptom Screening in Real-World Outpatient Settings: Correlations Between Patient-, Caregiver-, and Clinician-Reported Assessments in the RE-KINECT Study

Objective: To document possible tardive dyskinesia (TD) in psychiatric outpatients, as assessed by patients, caregivers, and clinicians.

Huda Shalhoub , PhD;

Jun Chen , MS, MSc;

Caroline Tanner , MD;